HC Wainwright upgraded shares of Solaris Resources (CVE:SLS – Free Report) to a strong-buy rating in a research report report published on Monday, Zacks.com reports. HC Wainwright also issued estimates for Solaris Resources’ FY2024 earnings at ($0.45) EPS and FY2025 earnings at ($0.47) EPS.
Several other equities analysts also recently commented on the stock. Maxim Group upgraded shares of Solaris Resources to a strong-buy rating in a research note on Wednesday, July 3rd. National Bank Financial upgraded shares of Solaris Resources to a strong-buy rating in a research report on Monday, June 10th.
Check Out Our Latest Research Report on Solaris Resources
Solaris Resources Trading Down 2.7 %
About Solaris Resources
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Recommended Stories
- Five stocks we like better than Solaris Resources
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- How to Use the MarketBeat Dividend Calculator
- Jeff Brown’s Exegesis AI Stock Picks
- The Most Important Warren Buffett Stock for Investors: His Own
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.